Who are Bismuth-based susceptibility-guided treatment's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/bismuth-based-susceptibility-guided-treatment.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Bismuth-based susceptibility-guided treatment — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Bismuth-based susceptibility-guided treatment (Bismuth-based susceptibility-guided treatment) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antimicrobial combination therapy (bismuth-based). Area: Gastroenterology / Infectious Disease.

marketed Antimicrobial combination therapy (bismuth-based) Helicobacter pylori cell wall and bacterial proteins Gastroenterology / Infectious Disease Small molecule Live · refreshed every 30 min

Target snapshot

Bismuth-based susceptibility-guided treatment (Bismuth-based susceptibility-guided treatment) — National Cheng-Kung University Hospital. Bismuth-based susceptibility-guided treatment uses antimicrobial susceptibility testing to direct personalized bismuth-containing regimens for Helicobacter pylori eradication.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Bismuth-based susceptibility-guided treatment TARGET	Bismuth-based susceptibility-guided treatment	National Cheng-Kung University Hospital	marketed	Antimicrobial combination therapy (bismuth-based)	Helicobacter pylori cell wall and bacterial proteins

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antimicrobial combination therapy (bismuth-based) class)

National Cheng-Kung University Hospital · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Bismuth-based susceptibility-guided treatment — Competitive Intelligence Brief. https://druglandscape.com/ci/bismuth-based-susceptibility-guided-treatment. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab